1172625-04-5

Basic information

• Product Name: 4,5-bis(2-Methoxyethoxy)-2-nitrobenzaMide
• Synonyms: 4,5-bis(2-Methoxyethoxy)-2-nitrobenzaMide
• CAS NO: 1172625-04-5
• Molecular Formula: C₁₃H₁₈N₂O₇
• Molecular Weight: 314.29122
• EINECS: -0
• Mol File: 1172625-04-5.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 439.9±45.0 °C(Predicted)
• Appearance: /
• Density: 1.273±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 15.09±0.50(Predicted)
• CAS DataBase Reference: 4,5-bis(2-Methoxyethoxy)-2-nitrobenzaMide(CAS DataBase Reference)
• NIST Chemistry Reference: 4,5-bis(2-Methoxyethoxy)-2-nitrobenzaMide(1172625-04-5)
• EPA Substance Registry System: 4,5-bis(2-Methoxyethoxy)-2-nitrobenzaMide(1172625-04-5)

Safety Data

• Hazardous Substances Data: 1172625-04-5(Hazardous Substances Data)

Upstream product

• 80407-64-3 3,4-bis(2-methoxyethoxy)benzaldehyde 
• 236750-65-5 4,5-bis(2-methoxyethoxy)-2-nitrobenzonitrile 
• 80407-68-7 3,4-bis(2-methoxyethoxy)-benzonitrile 
• 17345-61-8 3,4-dihydroxybenzonitrile 

Downstream Products

• 183322-18-1 4-chloro-6,7-bis(2-methoxyethoxy)quinazoline 
• 183319-69-9 erlotinib hydrochloride 
• 179688-29-0 6,7-bis(2-methoxyethoxy)-3,4-dihydroquinazolin-4-one 
• 236750-62-2 2-amino-4,5-bis[(2-methoxy)ethoxy]benzamide 

Relevant articles and documents

Method for preparing compound

The invention provides a method for preparing a compound as shown in a formula I which is described in the specification. The method comprises a step of contacting a compound as shown in a formula III which is described in the specification or a derivative thereof with a compound as shown in a formula II which is described in the specification so as to obtain the compound as shown in the formula I. In the formulas, R1 and R2 are hydrogen, alkoxy groups or heteroaromatic rings, preferably alkoxy groups; and R is hydrogen, an alkyl group, a phenyl group, a substituted phenyl group or a naphthyl group. The compound as shown in the formula I is a tinib drug intermediate 6,7-disubstituted quinazolinone. According to the method provided in embodiments in the invention, aldoketones are used as cyclization raw materials in replacement of carboxylic acids for preparation of tinib drug intermediate, and since the aldoketones are not corrosive, the method has low requirements on reaction equipment and is more favorable for industrial production.

COMPOUNDS FOR USE IN INHIBITING HIV CAPSID ASSEMBLY

The present invention relates to a compound or a pharmaceutically acceptable salt or solvate thereof for use in inhibiting HIV capsid assembly, the compound comprising the core structure wherein E is CR7or S, and wherein f is 0 or 1, and wherein in case E is S, f is 0, and wherein the core structure is at least substituted in 2 and 4 position, and wherein the residue R6 and R7, are, independently of each other, selected from the group consisting of -H, -D, -alkyl, alkoxy, alkenyl, alkynyl, halides, -NO2, - OH, -NH2, -NHR4#, -CN, - S(O)R4#, -SO2R4#, -P(O)R4#R5#, -P(O)(OR4#)R5#, -P(O)(OR4#)(OR5#), -C(O)NR4#R5#, - C(O)SR4#, -C(O)R4#, -C(O)O-R4#, alkoxy and glycol chains; and wherein R6 may optionally form a cyclic residue, with a further substituent present 5 or 6 position, and wherein R4# and R5# are, independently of each other, selected from the group consisting of -H, -alkyl, -alkenyl, -heterocyclo alkyl, aryl and heteroaryl.